Mark Groussman has resigned as a director of Therapix Biosciences Ltd.

Groussman's resignation was not related to any disagreement with the board on any matter relating to the operations, policies or practices, according to Therapix.

Tel Aviv, Israel-based Therapix Biosciences is a specialty clinical-stage pharmaceutical company that develops drugs based on cannabinoid molecules.